Life Biosciences Administers First Cellular Reprogramming Injection in Human Eye to Combat Aging
Life Biosciences, a Boston-based company, has initiated a groundbreaking trial by administering a cellular 'reprogramming' injection into the eye of a glaucoma patient. This experimental procedure aims to rejuvenate old cells, making them behave like young ones. The trial, which is in its early stages and approved by the FDA, involves fewer than 20 participants across various U.S. locations, including Boston, New York, Los Angeles, and Charleston. The therapy utilizes three of the four 'Yamanaka factors,' proteins known for their role in cellular reprogramming, while omitting the one associated with cancer risk. The process is controlled by a daily doxycycline pill, allowing for the therapy to be paused if safety concerns arise. This trial is a cautious step towards potential whole-body treatments that could extend healthy lifespans. 
